We interviewed 327 women who had been 50 to 74 years of age when treated for fracture of the hip of lower forearm, to determine their use (or lack of use) of estrogen preparations. Their responses were compared with those in a random sample of 567 women who were of similar age and from the same region. The risk of fracture was 50 to 60 per cent lower in women who had used these drugs for six years or longer than in women who hadnot used them (95 per cent confidence interval of relative risk, 0.3 to 0.6); those using them for shorter periods received less benefit, if any. A decreased risk of fracture was clearly evident only in women still taking estrogens and evident at either common daily dose (0.625 and 1.25 mg). In conjunction with the finding that estrogens can retard the development of osteoporosis in postmenopausal women, our data argue that lowering of the risk of hip and forearm fractures must be weighed as a benefit of long-term estrogen use.
This article has been cited by other articles:
MacLaughlin, E. J., Raehl, C. L.
(2008). ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults. Am J Health Syst Pharm
65: 343-357
[Full Text]
Kimmel, D.B.
(2007). Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates. J. Dent. Res.
86: 1022-1033
[Abstract][Full Text]
Kimmel, D.B.
(2007). Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates. FAKE JDR
86: 1022-1033
[Abstract][Full Text]
Labrie, F
(2006). Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA.. Endocr Relat Cancer
13: 335-355
[Abstract][Full Text]
Labrie, F, Luu-The, V, Belanger, A, Lin, S-X, Simard, J, Pelletier, G, Labrie, C
(2005). Is dehydroepiandrosterone a hormone?. J Endocrinol
187: 169-196
[Abstract][Full Text]
Rosendaal, F. R.
(2005). Venous Thrombosis: The Role of Genes, Environment, and Behavior. ASH Education Book
2005: 1-12
[Abstract][Full Text]
Sloane, P. D., Gruber-Baldini, A. L., Zimmerman, S., Roth, M., Watson, L., Boustani, M., Magaziner, J., Hebel, J. R.
(2004). Medication Undertreatment in Assisted Living Settings. Arch Intern Med
164: 2031-2037
[Abstract][Full Text]
Chu, S. P., Kelsey, J. L., Keegan, T. H. M., Sternfeld, B., Prill, M., Quesenberry, C. P., Sidney, S.
(2004). Risk Factors for Proximal Humerus Fracture. Am J Epidemiol
160: 360-367
[Abstract][Full Text]
Banks, E., Beral, V., Reeves, G., Balkwill, A., Barnes, I.
(2004). Fracture Incidence in Relation to the Pattern of Use of Hormone Therapy in Postmenopausal Women. JAMA
291: 2212-2220
[Abstract][Full Text]
The Women's Health Initiative Steering Committee,
(2004). Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial. JAMA
291: 1701-1712
[Abstract][Full Text]
Cauley, J. A., Robbins, J., Chen, Z., Cummings, S. R., Jackson, R. D., LaCroix, A. Z., LeBoff, M., Lewis, C. E., McGowan, J., Neuner, J., Pettinger, M., Stefanick, M. L., Wactawski-Wende, J., Watts, N. B.
(2003). Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density: The Women's Health Initiative Randomized Trial. JAMA
290: 1729-1738
[Abstract][Full Text]
Ma, Y. L., Bryant, H. U., Zeng, Q., Schmidt, A., Hoover, J., Cole, H. W., Yao, W., Jee, W. S. S., Sato, M.
(2003). New Bone Formation with Teriparatide [Human Parathyroid Hormone-(1-34)] Is Not Retarded by Long-Term Pretreatment with Alendronate, Estrogen, or Raloxifene in Ovariectomized Rats. Endocrinology
144: 2008-2015
[Abstract][Full Text]
Gallagher, J. C., Rapuri, P. B., Haynatzki, G., Detter, J. R.
(2002). Effect of Discontinuation of Estrogen, Calcitriol, and the Combination of Both on Bone Density and Bone Markers. J. Clin. Endocrinol. Metab.
87: 4914-4923
[Abstract][Full Text]
Gardner, M. J., Flik, K. R., Mooar, P., Lane, J. M.
(2002). Improvement in the Undertreatment of Osteoporosis Following Hip Fracture. JBJS
84: 1342-1348
[Abstract][Full Text]
Writing Group for the Women's Health Initiative In,
(2002). Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA
288: 321-333
[Abstract][Full Text]
Younan, C., Mitchell, P., Cumming, R. G., Panchapakesan, J., Rochtchina, E., Hales, A. M.
(2002). Hormone Replacement Therapy, Reproductive Factors, and the Incidence of Cataract and Cataract Surgery: : The Blue Mountains Eye Study. Am J Epidemiol
155: 997-1006
[Abstract][Full Text]
Galbiati, E., Caruso, P. L., Amari, G., Armani, E., Ghirardi, S., Delcanale, M., Civelli, M.
(2002). . J. Pharmacol. Exp. Ther.
300: 802-809
[Abstract][Full Text]
Marcus, R., Wong, M., Heath, H. III, Stock, J. L.
(2002). Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint. Endocr. Rev.
23: 16-37
[Abstract][Full Text]
Murphy, D. J., Gahm, G. J., Santilli, S., North, P., Oliver, S. C.N., Shapiro, H.
(2002). Seniors' Preferences for Cancer Screening and Medication Use Based on Absolute Risk Reduction. J. Gerontol. A Biol. Sci. Med. Sci.
57: M100-105
[Abstract][Full Text]
Cauley, J. A., Zmuda, J. M., Ensrud, K. E., Bauer, D. C., Ettinger, B.
(2001). Timing of Estrogen Replacement Therapy for Optimal Osteoporosis Prevention. J. Clin. Endocrinol. Metab.
86: 5700-5705
[Abstract][Full Text]
Grossman, J. M., MacLean, C. H.
(2001). Quality Indicators for the Management of Osteoporosis in Vulnerable Elders. ANN INTERN MED
135: 722-730
[Full Text]
Newcomb, P. A., Trentham-Dietz, A., Egan, K. M., Titus-Ernstoff, L., Baron, J. A., Storer, B. E., Willett, W. C., Stampfer, M. J.
(2001). Fracture History and Risk of Breast and Endometrial Cancer. Am J Epidemiol
153: 1071-1078
[Abstract][Full Text]
Compston, J. E.
(2001). Sex Steroids and Bone. Physiol. Rev.
81: 419-447
[Abstract][Full Text]
Rossberg, M. I., Murphy, S. J., Traystman, R. J., Hurn, P. D., Kontos, H. A.
(2000). LY353381.HCl, a Selective Estrogen Receptor Modulator, and Experimental Stroke Editorial Comment. Stroke
31: 3041-3046
[Abstract][Full Text]
Compston, J. E.
(2000). Pharmacological interventions for post-menopausal osteoporosis: an evidence-based approach. Rheumatology (Oxford)
39: 1309-1312
[Full Text]
Freedman, K. B., Kaplan, F. S., Bilker, W. B., Strom, B. L., Lowe, R. A.
(2000). Treatment of Osteoporosis: Are Physicians Missing an Opportunity?*{{dagger}}. JBJS
82: 1063-1063
[Abstract][Full Text]
Prestwood, K. M., Gunness, M., Muchmore, D. B., Lu, Y., Wong, M., Raisz, L. G.
(2000). A Comparison of the Effects of Raloxifene and Estrogen on Bone in Postmenopausal Women. J. Clin. Endocrinol. Metab.
85: 2197-2202
[Abstract][Full Text]
(1999). Hormone Replacement Therapy with Estrogen or Estrogen plus Medroxyprogesterone Acetate Is Associated with Increased Epithelial Proliferation in the Normal Postmenopausal Breast. J. Clin. Endocrinol. Metab.
84: 4559-4565
[Abstract][Full Text]
Goldstein, M. F., Fallon, J. J. Jr, Harning, R.
(1999). Chronic Glucocorticoid Therapy-Induced Osteoporosis in Patients With Obstructive Lung Disease*. Chest
116: 1733-1749
[Abstract][Full Text]
Gohel, A., McCarthy, M.-B., Gronowicz, G.
(1999). Estrogen Prevents Glucocorticoid-Induced Apoptosis in Osteoblasts in Vivo and in Vitro. Endocrinology
140: 5339-5347
[Abstract][Full Text]
Lawrence, M., Jones, L., Lancaster, T., Daly, E., Banks, E.
(1999). Hormone replacement therapy: patterns of use studied through British general practice computerized records. Fam Pract
16: 335-342
[Abstract][Full Text]
Perry, H. M. III
(1999). The Endocrinology of Aging. Clin. Chem.
45: 1369-1376
[Abstract][Full Text]
Col, N. F., Eckman, M. H., Wong, J. B.
(1999). Strategies for Individualizing Patient Decisions About Hormone Therapy. J. Clin. Endocrinol. Metab.
84: 1799-1802
[Full Text]
Recker, R. R., Davies, K. M., Dowd, R. M., Heaney, R. P.
(1999). The Effect of Low-Dose Continuous Estrogen and Progesterone Therapy with Calcium and Vitamin D on Bone in Elderly Women: A Randomized, Controlled Trial. ANN INTERN MED
130: 897-904
[Abstract][Full Text]
Sato, M., Zeng, G. Q., Rowley, E., Turner, C. H.
(1998). LY353381{middle dot}HCl: An Improved Benzothiophene Analog with Bone Efficacy Complementary to Parathyroid Hormone-(1-34). Endocrinology
139: 4642-4651
[Abstract][Full Text]
Sato, M., Turner, C. H., Wang, T., Adrian, M. D., Rowley, E., Bryant, H. U.
(1998). LY353381.HCl: A Novel Raloxifene Analog with Improved SERM Potency and Efficacy In Vivo. J. Pharmacol. Exp. Ther.
287: 1-7
[Abstract][Full Text]
Michaëlsson, K., Baron, J. A, Farahmand, B. Y, Johnell, O., Magnusson, C., Persson, P.-G., Persson, I., Ljunghall, S.
(1998). Hormone replacement therapy and risk of hip fracture: population based case-control study. BMJ
316: 1858-1863
[Abstract][Full Text]
Zumoff, B.
(1997). The Critical Role of Alcohol Consumption in Determining the Risk of Breast Cancer with Postmenopausal Estrogen Administration. J. Clin. Endocrinol. Metab.
82: 1656-1658
[Full Text]
Holloway, L., Kohlmeier, L., Kent, K., Marcus, R.
(1997). Skeletal Effects of Cyclic Recombinant Human Growth Hormone and Salmon Calcitonin in Osteopenic Postmenopausal Women. J. Clin. Endocrinol. Metab.
82: 1111-1117
[Abstract][Full Text]
Zhang, Y., Kiel, D. P., Kreger, B. E., Cupples, L. A., Ellison, R. C., Dorgan, J. F., Schatzkin, A., Levy, D., Felson, D. T.
(1997). Bone Mass and the Risk of Breast Cancer among Postmenopausal Women. NEJM
336: 611-617
[Abstract][Full Text]
LANE, J. M., RILEY, E. H., WIRGANOWICZ, P. Z.
(1996). Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Osteoporosis: Diagnosis and Treatment*{{dagger}}. JBJS
78: 618-32
[Full Text]
Grisso, J. A., Kelsey, J. L., Strom, B. L., O'Brien, L. A., Maislin, G., LaPann, K., Samelson, L., Hoffman, S., Northeast Hip Fracture Study Group,
(1994). Risk Factors for Hip Fracture in Black Women. NEJM
330: 1555-1559
[Abstract][Full Text]
Belchetz, P. E.
(1994). Hormonal Treatment of Postmenopausal Women. NEJM
330: 1062-1071
[Full Text]
Eaker, E., Hahn, R. A.
(1994). Women's Health Initiative. NEJM
330: 70-71
[Full Text]
Felson, D. T., Zhang, Y., Hannan, M. T., Kiel, D. P., Wilson, P., Anderson, J. J.
(1993). The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly Women. NEJM
329: 1141-1146
[Abstract][Full Text]
Ettinger, B., Grady, D.
(1993). The Waning Effect of Postmenopausal Estrogen Therapy on Osteoporosis. NEJM
329: 1192-1193
[Full Text]
Kadel, N. J., Teitz, C. C., Kronmal, R. A.
(1992). Stress fractures in ballet dancers. Am J Sports Med
20: 445-449
[Abstract]
Previous
